Combination chemotherapy for acute lymphoblastic leukaemia in adults.

Lister, T. Andrew; Whitehouse, J. M. A.; Beard, Michael; Brearley, Roger; Wrigley, P. F. M.; Oliver, R T; Freeman, J E; Woodruff, Roger; Malpas, J. S.; Paxton, A. M.; Crowther, Derek

doi:10.1136/bmj.1.6107.199

Cited by 110 publications

(31 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…W e report here the clinicopathological findings in 42 previously untreated adults with A L L tested for T and B cell markers and with an a n t i -A L L serum [6], and the prognostic significance of this phenotypic subdivision. [12]. The cell surface characteristics of 42 of these cases form the basis of this study.…”

Section: Introductionmentioning

confidence: 99%

Prognostic significance of cell surface phenotype in adult acute lymphoblastic leukaemia

Lister

Roberts

Brearley

et al. 1979

Cancer Immunol Immunother

View full text Add to dashboard Cite

Summary. Forty-two adults with acute lymphoblastie leukaemia were subgrouped according to the membrane marker characteristics of their blast cells. All patients received the same treatment at St. Bartholomew's Hospital The results indicate that the group expressing the common A L L antigen have a superior remission duration to the A L L antigen-negative, non-T, non-B A L L group and the T-ALL group. No correlation was evident between the first two subgroups and the clinical features of disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic significance of cell surface phenotype in adult acute lymphoblastic leukaemia

Lister

Roberts

Brearley

et al. 1979

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…Combination chemotherapy included adriamycin i.v., 30 m g/m 2 on day 1; vincristine i.v., 2 mg on day 1; ¿-asparaginase i.v., 10,000 units/m 2 from day I to day 14; dexamethasone 8.0 mg p.o. daily on days 1-21 [ Lister et al, 1978]. Blood coagulation tests, fib rinogen and AT III determinations were done in 14 ALL patients before and during this course of combi nation therapy.…”

Section: Methodsmentioning

confidence: 99%

“…2 adult ALL patients, reported in the present paper, were treated with a proto col including L-asparaginase [Lister et al, 1978] and died from pulmonary embo lism. This observation prompted us to un dertake a prospective study on the behav iour of AT III and fibrinogen during L-as paraginase therapy in a group of patients with ALL.…”

Section: Introductionmentioning

confidence: 99%

Fatal Pulmonary Embolism and Antithrombin III Deficiency in Adult Lymphoblastic Leukaemia during L-Asparaginase Therapy

et al. 1983

View full text Add to dashboard Cite

We describe 2 adult patients with acute lymphoblastic leukaemia (ALL) who died from pulmonary embolism following L-asparaginase treatment. Since this drug is known to cause a decrease in antithrombin III, the most important protein physiologically involved in the neutralization of thrombin, we studied the behaviour of this inhibitor in 14 ALL patients treated with a protocol including a 14-day course of L-asparaginase. A significant but transient fall of biological and immunological antithrombin III and a concomitant reduction of fibrinogen were documented.

show abstract

“…Comparison is made with the outcome for 111 patients of similar age distribution treated at SBH between 1972 and 1982 with two treatment programmes, 'OPAL' and 'HEAV'D', as previously reported (Lister et al, 1978;Barnett et al, 1986) (Bollum, 1979). The results were interpreted according to the following classification.…”

mentioning

confidence: 99%

High dose cytosine arabinoside in the initial treatment of adults with acute lymphoblastic leukaemia

Rohatiner

Bassan²,

Battista³

et al. 1990

Br J Cancer

View full text Add to dashboard Cite

In a study conducted at St Bartholomew's Hospital between 1972 and 1982, using moderately intensive therapy (OPAL/HEAV'D), a low blast count at presentation (less than 10 x 10(9) 1(-1)) and common ALL (C-ALL) phenotype correlated favourably with duration of remission. Fifty-four patients (age range 15-57, median 32) subsequently received a modification of the previous treatment programme which included high-dose ara-C 2 g m-2 b.d. for 6 days as cycle 3 (OPAL + HD ARA-C). CR was achieved in 36/54 (67%) patients, response correlating favourably with younger age (15-30 years vs 31-57 years, P = 0.02). Three patients died in CR. Overall, there was no difference in survival or remission duration between patients who received high dose ara-C and those in the control group. However, in contrast to the early results, there was a reversal in the relevance of the prognostic factors with a trend in favour of high blast count (greater than 10 x 10(9) 1(-1)) and T-cell phenotype in terms of remission duration. Moreover, comparison of duration of remission for the previously defined prognostic groups according to therapy suggests that the prognosis of patients with 'high risk' disease (T, B, null ALL or high blast count) is improved with more intensive therapy. In contrast, those with 'low risk' disease (C-ALL and low blast count) have a better prognosis with less intensive therapy. These observations confirm those of others and allow for individualization of therapy on the basis of pre-treatment variables.

show abstract

Combination chemotherapy for acute lymphoblastic leukaemia in adults.

Cited by 110 publications

References 13 publications

Prognostic significance of cell surface phenotype in adult acute lymphoblastic leukaemia

Prognostic significance of cell surface phenotype in adult acute lymphoblastic leukaemia

Fatal Pulmonary Embolism and Antithrombin III Deficiency in Adult Lymphoblastic Leukaemia during L-Asparaginase Therapy

High dose cytosine arabinoside in the initial treatment of adults with acute lymphoblastic leukaemia

Contact Info

Product

Resources

About